In Cell this week: strategies for targeting leukemia with MLL translocations, new Perturb-seq approach, and more.
The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.
Peter Nowell, one of the discoverers of the Philadelphia chromosome, has died.
The research used multiple genetic analyses on samples collected over 29 years to show changes associated with disease progression.
In Science this week: genetic analysis of pollutant-tolerant fish, and more.
A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.
Response to a low toxicity drug called decitabine was most pronounced in acute myeloid leukemia and myelodysplastic syndrome cases with TP53 mutations.
Roughly one-fifth of adult cases of acute lymphoblastic leukemia are marked by Philadelphia chromosome-like expression.
New studies touched on epigenetic, regulatory, and transcriptional features for brain, kidney, and breast tumors as well as various blood cancer types.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.